TREMFYA

all catalysts(0)

nothing on the calendar yet

News(9)

• MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
  MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
  fiercebiotech · 4d ago
• J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
  J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
  biopharma_dive · 1mo ago
• Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
  Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
  biopharma_dive · 1mo ago
• Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
  The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
  biopharma_dive · 2mo ago
• AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
  🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…
  endpoints · 2mo ago
• Avalo shares spike on skin drug data; BioNTech to cut staff
  Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
  biopharma_dive · 3mo ago
• J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
  Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…
  endpoints · 3mo ago
• STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
  HHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressants
  stat · 3mo ago
• STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
  A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
  stat · 3mo ago